| Company Name: |
Jinan Kabotang Biological Technology Co.,Ltd.
|
| Tel: |
0531-61320525 15866703830 |
| Email: |
figo.gao@foxmail.com |
| Products Intro: |
Product Name:Benzaldehyde, 2-hydroxy-6-[[(3S)-4-[[2-(2-hydroxyethyl)-3-pyridinyl]carbonyl]-3-morpholinyl]methoxy]-
CAS:2417955-18-9
Purity:98% HPLC Package:1kg
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:Osivelotor
CAS:2417955-18-9
Package:50mg;5mg
|
Benzaldehyde, 2-hydroxy-6-[[(3S)-4-[[2-(2-hydroxyethyl)-3-pyridinyl]carbonyl]-3-morpholinyl]methoxy]- manufacturers
- Osivelotor
-
- $0.00 / 50mg
-
2025-09-22
- CAS:2417955-18-9
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | Benzaldehyde, 2-hydroxy-6-[[(3S)-4-[[2-(2-hydroxyethyl)-3-pyridinyl]carbonyl]-3-morpholinyl]methoxy]- Basic information |
| | Benzaldehyde, 2-hydroxy-6-[[(3S)-4-[[2-(2-hydroxyethyl)-3-pyridinyl]carbonyl]-3-morpholinyl]methoxy]- Chemical Properties |
| Boiling point | 637.5±55.0 °C(Predicted) | | density | 1.338±0.06 g/cm3(Predicted) | | form | Solid | | pka | 7.79±0.10(Predicted) | | color | White to light yellow |
| | Benzaldehyde, 2-hydroxy-6-[[(3S)-4-[[2-(2-hydroxyethyl)-3-pyridinyl]carbonyl]-3-morpholinyl]methoxy]- Usage And Synthesis |
| Description | Osivelotor is an allosteric modulator of haemoglobin S. | | Uses | Osivelotor is an orally effective small molecule. Osivelotor is an allosteric regulator of deoxyhemoglobin S (HbS). Osivelotor increases the affinity of HbS to oxygen, inhibits HbS polymerization, and thus prevents erythrocyte sickling in the blood. Osivelotor can be used for research of sickle cell disease (SCD) [1] [2]. | | in vivo | Osivelotor (20-150 mg/kg; Oral gavage; Once a day; 21 days) significantly improves red blood cell health, reduces red blood cell sickle response and maintains oxygen delivery to peripheral tissues in a mouse model of sickle cell disease [2]. | Animal Model: | Male knock-in Townes mice with an HbSS genotype [2] | | Dosage: | 20, 40, 75 and 150mg/kg | | Administration: | Oral gavage (i.g.); once a day; 21 days | | Result: | Reduced red blood cell sickling, improved red blood cell deformability and prolonged red blood cell half-life.
Restored haemoglobin levels to the normal range.
Improved oxygen delivery and increased tolerance to severe hypoxia. |
| | References | [1] WHO Drug Information-World Health Organization (WHO).
[2] Dufu K, et al. GBT021601 improves red blood cell health and the pathophysiology of sickle cell disease in a murine model. Br J Haematol. 2023 Jul;202(1):173-183. DOI:10.1111/bjh.18771 |
| | Benzaldehyde, 2-hydroxy-6-[[(3S)-4-[[2-(2-hydroxyethyl)-3-pyridinyl]carbonyl]-3-morpholinyl]methoxy]- Preparation Products And Raw materials |
|